Publication details
Změny farmakokinetiky léčiv u dětských pacientů s IBD
| Title in English | Changes of drug's pharmacokinetics in pediatric IBD |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Appeared in Conference without Proceedings |
| MU Faculty or unit | |
| Citation | |
| Description | The pharmacokinetics of a drug can be influenced by a variety of factors, including the disease itself. In IBD, there may be changes in intestinal mucosal permeability, nutritional status and downstream distribution volumes, albumin transport capacity, or metabolic rate in hepatopathies. This can lead to significant changes in the plasma concentrations of the drugs administered and consequently alter their efficacy or toxicity. On the other hand, the drugs themselves can also significantly interfere with pharmacokinetic processes and thus affect co-administered substances. The above factors are more likely to affect the pharmacokinetics of conventional therapy with small molecule synthetic agents and 'traditional' pharmacokinetics such as salicylates and immunosuppressants, whereas biologics from the monoclonal antibody group will be less affected. |